Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Voyager Therapeutics excels in 2022, poised for CNS therapeutic breakthroughs

Voyager Therapeutics demonstrated strong performance in 2022, leveraging key partnerships and advancements in their pipeline programs to drive innovation and growth in the CNS therapeutics space.
While facing challenges in operational clarity and regulatory hurdles, the company's scientific strengths and financial stability position it well to capitalize on opportunities for expanding collaborations and advancing novel therapeutic approaches.
With a focus on CNS delivery, tissue targeting, and surrogate markers, Voyager is poised to make significant strides in addressing neurological disorders and enhancing treatment efficacy, offering potential value for investors and patients alike.

Voyager Therapeutics reports strong Q1 earnings and strategic advancements

Voyager Therapeutics showcased robust financial performance and strategic advancements in neurotherapeutics and gene therapy, positioning the company for future growth.
While facing challenges related to animal model predictability and reimbursement considerations, Voyager is actively leveraging strengths in diversified therapeutic approaches and strategic partnerships.
Opportunities lie in exploring synergistic treatments, proactive risk mitigation, and innovative therapeutic strategies to address complex neurological disorders effectively.
Overall, Voyager's focus on innovation, strategic partnerships, and comprehensive drug development approaches underscores its commitment to advancing treatments for neurological diseases.

Voyager Therapeutics excels in Q2, poised for neurogenetic medicine expansion

Voyager Therapeutics demonstrated strong financial health, innovative advancements in CNS programs, and strategic partnerships driving revenue growth. While facing challenges in R&D management and program milestones, the company's opportunities lie in upcoming milestones and expansion in neurogenetic medicine.

Voyager Therapeutics advances CNS gene therapy with strong partnerships and cash balance

Voyager Therapeutics is making strides in CNS gene therapy delivery with strong financial backing
Facing challenges in toxicology studies and patient recruitment while eyeing collaboration opportunities
Opportunities lie in biomarker utilization, partnership models, and advancing key programs towards clinical milestones

Voyager Therapeutics reports robust earnings and advances in neurogenetic therapies

Voyager Therapeutics showcased a strong financial performance, progress in their pipeline programs, and a focus on innovation and differentiation in the gene therapy space.
While facing competition and regulatory challenges, the company's strategic strengths, collaborations, and positive data present opportunities for future growth and impact.
Analysts' inquiries into program progress and regulatory timelines underscore investor interest in Voyager's development trajectory and the potential of their neurogenetic therapies.
With a robust financial position, promising pipeline advancements, and a commitment to unique approaches, Voyager is poised to make significant strides in the treatment of neurological disorders.

Voyager Therapeutics excels in Q1, eyes Alzheimer's breakthroughs

Voyager Therapeutics demonstrated strong financial performance and pipeline advancements in Q1 2024.
The company's focus on neurogenetic medicine and innovative gene therapy programs is a key strength.
Challenges include demonstrating efficacy in ALS therapy and optimizing brain delivery methods.
Opportunities lie in exploring novel treatment approaches and anticipating key data releases.

Voyager Therapeutics excels in Q2 with innovative pipeline advancements

Voyager Therapeutics demonstrated strong performance in Q2 2024, focusing on key milestones, tau-directed programs, and derisking strategies.
While facing challenges in program optimization and competitive positioning, the company's strengths lie in innovative pipeline advancements and financial stability.
Opportunities for multi-organ specificity, disease-specific programs, and treatment refinement position Voyager for continued growth and therapeutic innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Does Voyager Therapeutics (VYGR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Voyager Therapeutics (VYGR) Is Up 21.18% in One Week: What You Should Know

SQL Technologies Corp

SOC Telemed

Are these high-flying stocks smart picks to buy now?

3 Nasdaq Stocks That Have Soared 132% to 1,278% This Year

Voyager has been very lucky; it has got a second chance in a market that's averse to even giving first chances.

Voyager Does A Reboot After First Generation Failures

Shares of Voyager Therapeutics Inc. VYGR, +7.45% gained 2.9% in premarket trading on Tuesday after the gene therapy company said it hired former Biogen Inc. BIIB, -0.84% executive Dr. Alfred Sandrock Jr. as its CEO. Sandrock replaces interim CEO Michael Higgins, who will remain board chair.

Voyager names former Biogen executive Alfred Sandrock as CEO

Renowned neuroscientist brings pioneering drug development expertise and vision to emerging leader in next-generation AAV gene therapy Renowned neuroscientist brings pioneering drug development expertise and vision to emerging leader in next-generation AAV gene therapy

Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D.

Voyager Therapeutics has promising technology. But the stock is very risky.

Pfizer and Novartis Are Betting On This Under-the-Radar Biotech. Should You?

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Voyager Therapeutics (VYGR) Surges 12.1%: Is This an Indication of Further Gains?

Is it a good or bad thing when a stock experiences a golden cross technical event?

After Golden Cross, Voyager Therapeutics (VYGR)'s Technical Outlook is Bright

License option agreement with Novartis for target-specific access to TRACER™  next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

Novartis

Novartis AG (NYSE: NVS) has entered a license option agreement with Voyager Therapeutics Inc (NASDAQ: VYGR) for three capsids to use in potential gene therapies for neurological diseases, with an option to access capsids for two other targets. Data suggest that AAV capsids.

Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs

Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties

Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Voyager Therapeutics (VYGR) Report Negative Q4 Earnings? What You Should Know

Accomplished drug developer to help further long-term strategy, external scientific and business collaborations

Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics' Board of Directors and Newly Formed Executive Committee

After making a strategic shift and losing its CEO on the way, VYGR is back with a new platform and a new big pharma deal.This time could be different, but we are sure we thought so last time, too.

Voyager Therapeutics: Another Year, Another Deal

Voyager Therapeutics Inc (NASDAQ: VYGR) announced preclinical data from a new vectorized anti-HER2 antibody program. Data showed that IV dosing of a proprietary AAV vector identified by the TRACER screening technology, encoding an anti-HER2 antibody payload, prevented tumor growth in animal models of brain metastases.

Voyager Therapeutics's Cancer Antibody Program Shows Encouraging Preclinical Action

Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS

Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting

CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced it will present preclinical data from its vectorized antibody program at the 26th Society for Neuro-Oncology (SNO) Annual Meeting on Nov. 19, 2021.

Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.67% and -25.90%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue Estimates

License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestone payments plus royalties in exchange for access to TRACER™ novel capsids for use with two Pfizer transgenes in neurologic and cardiovascular disease

Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results

Earnings Preview: Voyager Therapeutics (VYGR) Q3 Earnings Expected to Decline

Vinco Ventures

Bitfarms Ltd

Clovis Oncology

Kala Pharmaceuticals

Meta Materials

Romeo Power

Senseonics Holdings

Electrameccanica

Wish

If you're like most traders right now, you're looking for an edge.… The post Best Penny Stocks To Buy For A Short Squeeze?

Best Penny Stocks To Buy For A Short Squeeze? 10 To Watch Today

Voyager Therapeutics Inc (NASDAQ: VYGR) has announced the presentation of preclinical data of GBA1 gene replacement therapy. The data demonstrated that a single intravenous (IV) dose of GBA1 gene replacement therapy achieved widespread distribution in the central nervous system (CNS) and peripheral tissues and substantially raised levels of the GCase enzyme in animal models.

Voyager Posts Encouraging Preclinical Data For CNS-Directed Gene Therapy

Single AAV intravenous dose achieved widespread CNS distribution and sustained correction of GCase activity in multiple brain regions Single AAV intravenous dose achieved widespread CNS distribution and sustained correction of GCase activity in multiple brain regions

Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy

Advaxis

ReShape Lifesciences

Are these high volume biotech penny stocks worth adding to your watchlist right now? The post Top Biotech Penny Stocks to Watch With High Volume Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Biotech Penny Stocks to Watch With High Volume Right Now

Investors need to pay close attention to Voyager (VYGR) stock based on the movements in the options market lately.

News for Voyager Therapeutics Stock (VYGR)